Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company that regularly issues news about its small molecule programs for cancer and genetic disease. Company updates frequently highlight progress for its lead PI3Kα program, RLY-2608, also referred to as zovegalisib, and the use of its Dynamo® platform to address challenging protein targets.
Investors and followers of RLAY news can expect detailed announcements on clinical trial milestones, including interim and subset analyses from the ReDiscover first-in-human study and the Phase 3 ReDiscover-2 trial in HR+/HER2- breast cancer with PI3Kα mutations. Press releases have described efficacy measures such as progression-free survival and objective response rates, as well as safety and tolerability profiles for zovegalisib or RLY-2608 in combination with agents like fulvestrant and CDK inhibitors.
Relay Therapeutics also issues corporate and financial updates, such as quarterly financial results, cash runway commentary, and changes to its Board of Directors. These items are often accompanied by Form 8-K filings and may include information on research and development spending, general and administrative expenses, and net loss figures, without serving as investment advice.
Additional news items cover participation in healthcare and biotechnology investor conferences, where company management joins fireside chats hosted by firms such as Jefferies, Goldman Sachs, Wells Fargo, Guggenheim and Morgan Stanley. These events provide further context on strategy, the Dynamo platform, and the clinical pipeline, including programs for NRAS-driven solid tumors and Fabry disease.
This news page aggregates such disclosures so readers can follow Relay Therapeutics’ clinical progress, scientific presentations at meetings like ASCO and SABCS, and ongoing corporate developments related to the RLAY stock.
Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases, has announced its participation in two major investor conferences in September 2025.
Management will engage in fireside chats at the 2025 Wells Fargo Healthcare Conference on September 4 at 2:15 p.m. ET and the Morgan Stanley 23rd Annual Global Conference on September 10 at 11:30 a.m. ET. Both presentations will be available via webcast on the company's investor relations website, with replays accessible for 30 days after the events.
Relay Therapeutics (NASDAQ:RLAY) reported Q2 2025 financial results and clinical updates, highlighting progress in its cancer treatment programs. The company's lead candidate RLY-2608 demonstrated promising results in Phase 1b trials for breast cancer, showing a 10.3-month median progression-free survival and 39% objective response rate in PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients.
The company has initiated its Phase 3 ReDiscover-2 trial comparing RLY-2608 + fulvestrant versus capivasertib + fulvestrant in HR+/HER2- breast cancer patients. Financial results showed a net loss of $70.4 million ($0.41 per share) and cash reserves of $656.8 million, expected to fund operations into 2029.
Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company, announced it will release its Q2 2025 financial results and corporate updates after market close on Thursday, August 7, 2025.
The company, which specializes in combining computational and experimental technologies for drug discovery, will provide details on its financial performance and business progress.
Relay Therapeutics (NASDAQ: RLAY), a clinical-stage precision medicine company, has announced its participation in two major investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 8:45 a.m. ET and the Goldman Sachs Global Healthcare Conference on June 11 at 2:40 p.m. ET. Both presentations will be accessible via live webcast through Relay's website, with recordings available for 30 days after each event.
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, has announced it will release its first quarter 2025 financial results and corporate highlights on Monday, May 5, 2025. The announcement will be made after U.S. financial markets close.
The company, based in Cambridge, Massachusetts, specializes in transforming drug discovery through a combination of:
- Leading-edge computational technologies
- Experimental technologies
This upcoming financial disclosure represents a standard quarterly reporting event for the precision medicine developer, providing stakeholders with insights into the company's financial performance and operational progress for Q1 2025.
Relay Therapeutics (RLAY) reported its Q4 and full year 2024 financial results, highlighting progress in its breast cancer program. The company plans to initiate the Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant in mid-2025 for PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients.
Key clinical data showed 11.4-month median PFS in second-line patients, with a 39% confirmed overall response rate and 67% Clinical Benefit Rate. The company ended Q4 2024 with $781.3 million in cash and investments, expected to fund operations into second half of 2027.
Financial results showed no revenue in Q4 2024, while full-year revenue decreased to $10.0 million from $25.5 million in 2023. R&D expenses were $68.1 million in Q4 2024, down from $77.5 million in Q4 2023. Net loss for Q4 2024 was $76.0 million ($0.45 per share), compared to $83.5 million ($0.67 per share) in Q4 2023.
Relay Therapeutics (RLAY), a clinical-stage precision medicine company, has announced its participation in two major investor conferences in March 2025. The company will be featured in fireside chat sessions at:
• TD Cowen's 45th Annual Health Care Conference on March 5, 2025, at 1:50 p.m. ET
• Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 11:00 a.m. ET
Both sessions will be accessible via live webcast through Relay Therapeutics' website in the News & Events section. Archived recordings will remain available for 30 days after each event. The company, known for combining computational and experimental technologies in drug discovery, makes these presentations available at https://ir.relaytx.com/news-events/events-presentations.